Dr. Jaume Kulisevsky, director of the Sant Pau Biomedical Research Institute (IIB Sant Pau) and director of the Movement Disorders Unit of the Neurology Service of the Sant Pau Hospital, coordinates the only European and multicentre study on Parkinson’s disease with dementia that is currently entering phase II.
This clinical study, in which 20 hospitals from all over Spain will participate, is being carried out with the approval of the Spanish Agency for Medicines and Health Products (AEMPS), to test the effectiveness of the drug ANAVEX®2-73 in this disease.
Translated with www.DeepL.com/Translator
